ONCOSCIENCE

oncoscience-logo

Oncoscience is a biopharmaceutical company. Oncoscience GmbH develops therapeutic options for rare diseases in oncology. Despite intensive research in oncology, the needs of adequate treatment of these orphan diseases often cannot be met by major pharmaceutical companies. Currently Oncoscience as part of Innokeys Pte Ltd accomplishes the clinical development of Nimotuzumab for Europe. Nimotuzumab is a monoclonal antibody that can be used for the treatment of several malignancies. Nimotuzumab has the status as orphan drug both in the US and Europe for diffuse intrinsic pontine glioma and pancreatic cancer

#People #Website #More

ONCOSCIENCE

Social Links:

Industry:
Biopharma Biotechnology Health Care Pharmaceutical Therapeutics

Founded:
2001-01-01

Address:
Schenefeld, Schleswig-Holstein, Germany

Country:
Germany

Website Url:
http://www.oncoscience.de

Status:
Active

Contact:
+49 40 3009799-0

Email Addresses:
[email protected]

Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SSL By Default Google Analytics WordPress Google Universal Analytics Apache Wordpress Plugins Gravatar Profiles DigiCert SSL


Current Employees Featured

not_available_image

Ferdinand Bach
Ferdinand Bach CEO & Founder @ Oncoscience
CEO & Founder

Founder


not_available_image

Ferdinand Bach

Official Site Inspections

http://www.oncoscience.de Semrush global rank: 5.32 M Semrush visits lastest month: 1.56 K

  • Host name: 217-160-0-137.elastic-ssl.ui-r.com
  • IP address: 217.160.0.137
  • Location: Germany
  • Latitude: 51.2993
  • Longitude: 9.491
  • Timezone: Europe/Berlin

Loading ...

More informations about "Oncoscience"

Oncoscience | HOME

Die Oncoscience GmbH entwickelt Therapieoptionen für seltene Erkrankungen im Bereich der Onkologie.See details»

Oncoscience | ABOUT

ABOUT US Oncoscience GmbH develops therapeutic options for rare diseases in oncology. Despite intensive research in oncology, the needs of adequate treatment of these orphan …See details»

Oncoscience | Nimotuzumab on ASCO 2022

Die Oncoscience GmbH entwickelt Therapieoptionen für seltene Erkrankungen im Bereich der Onkologie.See details»

Oncoscience - Crunchbase Company Profile & Funding

Oncoscience is a biopharmaceutical company. Oncoscience GmbH develops therapeutic options for rare diseases in oncology. Despite intensive research in oncology, the needs of adequate …See details»

Oncoscience GmbH Overview | SignalHire Company Profile

Oncoscience is a Germany based privately-owned biopharmaceutical company founded in 2001 to advance the development of novel products for the treatment of orphan indications in …See details»

Oncoscience - Overview, News & Competitors | ZoomInfo.com

View Oncoscience (www.oncoscience.de) location in Schleswig Holstein, Germany , revenue, industry and description. Find related and similar companies as well as employees by title and …See details»

Oncoscience Company Profile 2024: Valuation, Investors, …

Information on acquisition, funding, investors, and executives for Oncoscience. Use the PitchBook Platform to explore the full profile.See details»

Oncoscience - Craft

Oncoscience is a biopharmaceutical company that provides products for the treatment of orphan indications in oncology. It is engaged in the development of Nimotuzumab, a monoclonal …See details»

STARTSEITE - Oncoscience

Die Oncoscience GmbH entwickelt Therapieoptionen für seltene Erkrankungen im Bereich der Onkologie.See details»

EU/3/08/550 - European Medicines Agency

On 3 June 2008, orphan designation (EU/3/08/550) was granted by the European Commission to Oncoscience AG, Germany, for nimotuzumab for the treatment of pancreatic cancer. The …See details»

Oncoscience GmbH | Insights

Aug 15, 2008 Oncoscience AG has withdrawn its application to the EMEAfor marketing authorisation of the EGFR-targeted drug nimotuzumab for the treatment of paediatric glioma …See details»

Editorial Board - Oncoscience

Dafna Bar-Sagi NYU School of Medicine, New York, NYSee details»

Oncoscience | In the News

Oncoscience is one of the most prominent journals published by Impact Journals. Impact Journals will be participating as an exhibitor at the American Association for Cancer Research (AACR) …See details»

Archive of "Oncoscience". - PMC - National Center for …

Jan 18, 2015 Preview improvements coming to the PMC website in October 2024. Learn More or Try it out now.See details»

Oncoscience | Specific Pharma A/S and Oncoscience GmbH launch …

Nov 6, 2020 Die Oncoscience GmbH entwickelt Therapieoptionen für seltene Erkrankungen im Bereich der Onkologie.See details»

Volume 9, 2022 - Oncoscience

The cover for Oncoscience Volume 9, 2022 features Figure 2, "As expected, based on rapamycin-like p53-mediated gerosuppression, mTOR inhibition acts as a checkpoint ...See details»

ONCOLOGY - Oncoscience

Decades of intensive research in oncology have provided a variety of therapies for numerous cancer indications. Therefore, toady more than half of the affected patients in Germany can …See details»

Oncoscience | Volume 11, 2024

IPIAD- an augmentation regimen added to standard treatment of pancreatic ductal adenocarcinoma using already-marketed repurposed drugs irbesartan, pyrimethamine, …See details»

ONKOLOGIE - Oncoscience

ONKOLOGIE UND ORPHAN DRUGS Krebs ist eine der häufigsten Todesursachen weltweit (1) und ist z.B. in Deutschland die zweithäufigste Todesursache nach den kardiovaskulären …See details»

Oncoscience | Freeing oncology from publication cost

Oncoscience is an open-access, peer-reviewed, oncology-focused journal with a special mission: to free researchers from publication costs. Oncoscience is free for both readers and authors.See details»